{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"Proportion of participants developing any arterial or venous thromboembolic event","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set comprised of all randomized participants who received at least one dose of ruxolitinib or BAT.","reportingStatus":"POSTED","timeFrame":"From randomization to Week 80 for BAT and Week 260 for Ruxolitinib","title":"Number of Participants Developing Thrombosis","type":"SECONDARY","unitOfMeasure":"Participants"}